Med. praxi. 2018;15(1):26-29 | DOI: 10.36290/med.2018.004

Optimal treatment of venous thromboembolism

doc. MUDr. Radovan Malý, Ph.D.

I. interní kardioangiologická klinika, Fakultní nemocnice Hradec Králové, LF UK v Hradci Králové

Ústav ošetřovatelství, Fakulta veřejných politik v Opavě, Slezská Univerzita Opava

Venous thromboembolism involving deep vein thrombosis as well as pulmonary embolism represents a frequent and costlydisease that is associated with high morbidity and mortality rates. The main goal of treatment is to prevent pulmonary embolismand death related to venous thrombosis and pulmonary embolism as well as to prevent chronic venous insufficiency and chronicthromboembolic pulmonary hypertension. In addition to treatment with low-molecular-weight heparin and warfarin, there hasbeen a trend in the last five years to increasingly use direct oral anticoagulants in treatment; these include the so-called xabans(rivaroxaban, apixaban, edoxaban), direct inhibitors of activated factor Xa, and the so-called gatrans, including dabigatran thatinhibits activated factor IIa. The case report presents modern methods of treating acute-stage venous thromboembolism andsubsequent secondary long-term prophylaxis in a patient with recurrent venous thrombosis who, in the course of treatment,had to undergo acute surgery with the need to administer an antidote in order to rapidly eliminate the anticoagulant effect ofdabigatran from the body.

Keywords: venous thromboembolism, treatment, DOAC (direct oral anticoagulants), dabigatran

Published: March 1, 2018  Show citation